Related Experiment Videos
Antidepressant dosing and switching guidelines: focus on nefazodone
John Zajecka1, Geoffry W McEnany, Kimberly M Lusk
1Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill 60612, USA. jzajecka@rush.edu
The Journal of Clinical Psychiatry
|March 14, 2002
Summary
Optimizing antidepressant dosing, particularly with nefazodone, balances patient safety and treatment efficacy. Doses between 300-600 mg/day are effective for major depression with low adverse event discontinuation rates.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Therapeutics
Background:
- Dosing strategies are critical in balancing patient-reported outcomes (efficacy, safety, adherence) and provider-driven care (symptom identification, drug selection).
- Effective dosing can mitigate adverse effects, improve patient comfort, and enhance treatment response.
- Antidepressant dosing is particularly important when switching medications due to suboptimal efficacy of the initial agent.
Purpose of the Study:
- To evaluate the efficacy and safety profile of nefazodone for major depression management.
- To establish optimal dosing ranges for nefazodone in treating acute, severe, and chronic major depression, including relapse prevention.
Main Methods:
- Review of clinical trial data for nefazodone in major depression.
- Analysis of response rates and adverse event profiles across different dosage levels.
Main Results:
- Nefazodone demonstrates comparable response rates to imipramine and most selective serotonin reuptake inhibitors (SSRIs).
- The efficacy of nefazodone is most clearly established within the 300-600 mg/day dosage range.
- Discontinuation rates due to adverse events are low within this effective dose range.
Conclusions:
- Nefazodone is an effective treatment option for major depression, offering comparable efficacy to existing antidepressants.
- A daily dosage of 300-600 mg of nefazodone is recommended for optimal efficacy and a favorable safety profile.
- Appropriate nefazodone dosing supports effective management of major depression and relapse prevention with minimal adverse event-related discontinuations.